Are we ready to predict late effects? A systematic review of clinically useful prediction models Journal Article

Authors: Salz, T.; Baxi, S. S.; Raghunathan, N.; Onstad, E. E.; Freedman, A. N.; Moskowitz, C. S.; Dalton, S. O.; Goodman, K. A.; Johansen, C.; Matasar, M. J.; De Nully Brown, P.; Oeffinger, K. C.; Vickers, A. J.
Article Title: Are we ready to predict late effects? A systematic review of clinically useful prediction models
Abstract: Background After completing treatment for cancer, survivors may experience late effects: consequences of treatment that persist or arise after a latent period. Purpose To identify and describe all models that predict the risk of late effects and could be used in clinical practice. Data sources We searched Medline through April 2014. Study selection Studies describing models that (1) predicted the absolute risk of a late effect present at least 1 year post-treatment, and (2) could be used in a clinical setting. Data extraction Three authors independently extracted data pertaining to patient characteristics, late effects, the prediction model and model evaluation. Data synthesis Across 14 studies identified for review, nine late effects were predicted: erectile dysfunction and urinary incontinence after prostate cancer; arm lymphoedema, psychological morbidity, cardiomyopathy or heart failure and cardiac event after breast cancer; swallowing dysfunction after head and neck cancer; breast cancer after Hodgkin lymphoma and thyroid cancer after childhood cancer. Of these, four late effects are persistent effects of treatment and five appear after a latent period. Two studies were externally validated. Six studies were designed to inform decisions about treatment rather than survivorship care. Nomograms were the most common clinical output. Conclusion Despite the call among survivorship experts for risk stratification, few published models are useful for risk-stratifying prevention, early detection or management of late effects. Few models address serious, modifiable late effects, limiting their utility. Cancer survivors would benefit from models focused on long-term, modifiable and serious late effects to inform the management of survivorship care. © 2015 Elsevier Ltd. All rights reserved.
Keywords: review; treatment planning; sensitivity and specificity; neoplasms; breast cancer; heart disease; morbidity; validation study; cancer therapy; childhood cancer; hodgkin disease; cancer survivor; risk assessment; risk; survivors; prostate cancer; lymphedema; dysphagia; statistical analysis; head and neck cancer; systematic review; early diagnosis; urine incontinence; heart failure; mental disease; medline; therapy effect; multivariate analysis; thyroid cancer; erectile dysfunction; nomogram; secondary prevention; cardiomyopathy; decision support techniques; latent period; human; priority journal; evaluation study
Journal Title: European Journal of Cancer
Volume: 51
Issue: 6
ISSN: 0959-8049
Publisher: Elsevier Inc.  
Date Published: 2015-04-01
Start Page: 758
End Page: 766
Language: English
DOI: 10.1016/j.ejca.2015.02.002
PROVIDER: scopus
PUBMED: 25736818
PMCID: PMC4518853
Notes: Export Date: 4 May 2015 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Talya Salz
    31 Salz
  2. Karyn A Goodman
    244 Goodman
  3. Chaya S. Moskowitz
    172 Moskowitz
  4. Kevin Oeffinger
    255 Oeffinger
  5. Shrujal S Baxi
    69 Baxi
  6. Andrew J Vickers
    556 Vickers
  7. Matthew J Matasar
    119 Matasar